Taiwan Advance Bio-Pharmaceutical Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported negative sales was TWD 0.549 million compared to TWD 0.403 million a year ago. Revenue was TWD 243.36 million compared to TWD 235.57 million a year ago. Net loss was TWD 118.53 million compared to TWD 86.39 million a year ago. Basic loss per share from continuing operations was TWD 1.32 compared to TWD 1.07 a year ago.